About this event

  • Date and time Thu 25 Jan 2024 from 8:30am to 5:00pm
  • Location Royal Society of Medicine
  • Organised by Oncology, Obstetrics and Gynaecology

Join us for the first Royal Society of Medicine event dedicated to endometrial cancer. 

There has been progress in our molecular knowledge of the disease and multi-disciplinary treatment of endometrial cancer in recent years. In the last year, landmark clinical trials are changing clinical practice integrating molecular testing and immunotherapy in treatment decisions. This meeting will provide an overview of the latest cutting-edge results setting new standards in endometrial cancer management, including updates on staging, pathology and molecular testing, surgery, radiotherapy and drug treatments.

Our multi-disciplinary faculty of national and international experts will provide in-depth presentations and discussions on controversial areas to guide the best clinical practice for women with endometrial cancer.

By attending, you will:

  • Understand the rising incidence, survival, disparities and prevention strategies for endometrial cancer
  • Be able to make multidisciplinary decisions integrating staging and molecular status in early and advanced/recurrent endometrial cancer
  • Understand the latest immunotherapy clinical trials changing practice in endometrial cancer
  • Recognise and manage treatment-related toxicities of immunotherapy and targeted therapies in endometrial cancer
  • Improve knowledge of the latest advances and future perspectives in endometrial cancer treatment

Follow us on: 

Facebook 
Instagram 
LinkedIn 
Twitter 
YouTube 

We would like to thank our sponsors GSK, Eisai and MSD who have contributed funding towards this event through the purchase of stand space. We would also like to thank AstraZeneca who have provided a sponsorship grant towards this independent meeting. Please note the sponsors have had no input into the agenda or speakers for the meeting.

Key speakers

Dr Ana Oaknin

Dr Ana Oaknin

Head of the Gynaecological Cancer Programme, Vall d'Hebron Institute of Oncology 

Speaker's biography

Professor Oaknin is Head of the Gynaecological Cancer Programme at Vall d'Hebron Institute of Oncology and full attending physician at the Vall d'Hebron University Hospital. The aim of her career is clinical research. She has served as a principal investigator in many clinical studies, a few of them registrational studies. In addition, she is the author of distinguished articles in high-impact journals.

Professor Susana Banerjee

Professor Susana Banerjee

Prof Susana Banerjee, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust

Speaker's biography

Prof Susana Banerjee MBBS MA PhD FRCP is a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at The Royal Marsden NHS Foundation Trust, London. She is also Professor in Women’s Cancers at the Institute of Cancer Research. Dr Banerjee specialises in ovarian cancer and the systemic treatment of endometrial and cervical cancers.

 

Prof Banerjee graduated with a 1st class in Physiology from St John’s College, University of Cambridge. She was president of the Cambridge Medical Society in 1996-1997. She completed her medical training in 2000 at The Royal Free/University College London Medical School where she was a University of London Gold Medal finalist. Dr Banerjee gained a PhD from The Institute of Cancer Research in 2009, University of London and was awarded the San Antonio Breast Cancer Symposium Novartis Oncology Basic Science Award for her research. Other prizes include the Association of Cancer Physicians McElwain Prize, the Sir Antony Driver Prize and the Pfizer British Oncology Association Young Investigator Award (highly commended).

 

Prof Banerjee has served in international specialist groups including the European Organization for Research and Treatment of Cancer (EORTC) Executive Steering Committee for Gynaecological Cancers, ESGO (European Society of Gynaecological Oncology) Congress Faculty and International Gynecologic Cancer Society Scientific Program Committee. Prof Susana Banerjee was elected serve on the European Society of Medical Oncology (ESMO) Executive Board as Director of Membership (2020-2022). She was Track Chair for Gynaecological Cancers for the ESMO Congress 2018, Scientific Co-Chair for ESMO Asia 2018 and Co-Chair of the ESMO Gynaecological Cancers Congress 2021-2024. She is currently co-chair of the Gynecological Cancer InterGroup (GCIG) Rare Cancers Committee. She is a Theme Lead (Cancer Treatment Effects) for the National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research. Prof Banerjee is President-Elect of the Royal Society of Medicine Oncology Section.

 

Prof Banerjee is an author of over 175 peer-reviewed publications including in the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology and Annals of Oncology. Her research interests include individualisation of patient treatment, targeted therapies (including PARP inhibitors) and rare gynaecological cancers. Prof Banerjee has Global and UK Chief Investigator roles of over 30 national and international clinical trials.

Agenda

View the programme

Registration, tea and coffee
Welcome and introduction

Professor Susana Banerjee, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London

Session 1

Chairs: Professor Susana Banerjee, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, Dr Patrick O'Briend, Consultant in Obstetrics and Maternal Medicine University College London Hospitals and Mr Michael Savvas, Consultant Gynaecologist, King Edward VII's Hospital

The rise and challenge of endometrial cancer

Mr John Butler, Consultant Gynaecological Surgeon, The Royal Marsden NHS Foundation Trust

The emerging supportive needs of women with endometrial cancer

Andreia Fernandes, Lead Nurse for Gynae-Oncology, The Royal Marsden NHS Foundation Trust

Panel discussion
Tea and coffee break

Session 2

Chairs: Professor Susana Banerjee, Dr Patrick O'Briend and Mr Michael Savvas

Molecular classification and updated The International Federation of Gynecology and Obstetrics staging in endometrial cancer

Prof Glenn McCluggage, Consultant Histopathologist and Honorary Professor in Gynaecological Pathology, Queen’s University, Belfast

Molecular testing in clinical practice mismatch repair deficiency and beyond

Dr Angela George, Consultant Medical Oncologist, North Thames Genomic Laboratory Hub 

Panel Discussion
Surgical options for newly-diagnosed Endometrial Cancer

Dr Esther Moss, Associate Professor in Gynaecological Oncology, University of Leicester

Adjuvant radiotherapy decisions in endometrial cancer

Dr Melanie Powell, Consultant Clinical Oncologist, Bart’s Health NHS Trust

Panel discussion
Lunch break

Session 3

Chair: Dr Susana Banerjee, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London

First line Immunotherapy for advanced, metastatic or recurrent endometrial cancer : A new standard of care for all?

Dr Ana Oaknin, Head of the Gynaecological Tumour Unit, University, Barcelona

Current and future perspective: How to treat recurrent or advanced endometrial cancer beyond immunotherapy?

Professor Susana Banerjee, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London

Managing Immunotherapy Toxicities and targeted therapies in endometrial cancer

Dr Andrew Clamp, Consultant Medical Oncologist, The Christie NHS Foundation Trust,

Panel discussion
Tea and coffee break

Session 4

Chair: Professor Susana Banerjee, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London

Case discussions
Closing remarks

Professor Susana Banerjee, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London

Close of meeting

Sponsors

Location

Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom

Registration for this event will close on 24 January 2024 at 23:45pm (GMT). We are accepting on-the-day registrations. 

The agenda is subject to change at any time

If the event is recorded, we are only able to share presentations that we have received permission to share. There is no guarantee that all sessions will be available after the event, this is at the presenter’s and RSM’s discretion.

All views expressed at this event are of the speakers themselves and not of the Royal Society of Medicine, nor the speaker's organisations.

This event will be recorded and stored by the Royal Society of Medicine and may be distributed in future on various internet channels.